AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05499273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rapid sequence tracheotomy
Description: 1. Orientational palpation and vertical midline skin incision followed by separation of the strap muscles~2. Exposure of the trachea and cricoid followed by anterior luxation of the trachea with a Backhaus towel clamp~3. Perform a vertical puncture with a tip scissors between the cricoid and 1st tracheal ring followed by a vertical incision of no more than 2 rings in length.~4. A tracheal tube (inner diameter 3.0 mm, cuffed) is inserted to secure the airway permanently.
Study NCT05476393 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative management
Description: 1 g paracetamol will be administered 3 x 1. If the NRS score is ≥ 4, 1 mg kg-1 iv tramadol will be administrated.
Study NCT06382675 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Therapeutic Plasma Exchange (TPE) with the Plasma Filter PX2
Description: 272 evaluable TPE treatments will be documented in the study (with an average of 5-7 TPE treatments per patient this corresponds to approximately 46 patients)
Study NCT05705830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse magnetic therapy
Description: Pulse magnetic therapy SM-II (2019102133903)
Study NCT05705830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors （SSRI）
Description: Anti-anxiety Drugs
Study NCT05705830 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Selective serotonin reuptake inhibitors （SSRI）
Description: Anti-anxiety Drugs
Study NCT05705830 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Shame magnetic therapy
Description: Shame magnetic therapy
Study NCT05705830 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Shame magnetic therapy
Description: Shame magnetic therapy
Study NCT05293665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: UB-612 (100µg), 0.5mL suspension, intramuscular injection
Study NCT04247516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online-intervention group I (IGI)
Description: Narrative-based online intervention program to promote self-regulatory competences.
Study NCT04247516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online-intervention group II (IGII)
Description: Narrative-based online intervention program to promote self-regulatory competencies plus gamification strategies.
Study NCT06385171 — intervention group
Intervention type: DRUG
Intervention: Botulinum toxin type A
Description: The intervention involves the administration of Botulinum Toxin Type A, with dosages regulated according to FDA guidelines. Each injection site will receive a maximum of 4 units, adhering to the FDA's recommended dosage limits. Dosages administered will be tailored to each patient's needs and will be recorded in their individual patient information chart.
Study NCT05256823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Patients will be treated with Celecoxib twice daily for 48 weeks.
Study NCT05256823 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: nucleos(t)ide analogue
Description: Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
Study NCT05256823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nucleos(t)ide analogue
Description: Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
Study NCT04827277 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reverse Total Shoulder Replacement
Description: Participants will be randomized to a reverse total shoulder replacement
Study NCT04827277 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomic Total Shoulder Replacement
Description: Participants will be randomized to an anatomic total shoulder replacement
Study NCT05293665 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BNT162b2 vaccine
Description: BNT162b2 vaccine (30µg), 0.3mL suspension, intramuscular injection
Study NCT05660096 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cionic Neural Sleeve NS-100
Description: Sleeve applies neuromuscular stimulation as patients walk to help contract appropriate muscles at appropriate times.
Study NCT06521970 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The kyphosis angle
Description: The subject was positioned in a neutral standing position. the short side of the phone was placed on the T1-3 spinous process and the protractor was set to 0°. Subsequently, the phone was placed on the T12, and the angular value displayed on the screen was recorded as the kyphotic angle.
Study NCT06521970 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: dynamic postural performance
Description: The test measures spinal alignment deviations during static loading in the 90° shoulder flexion position. The test measurements are made in a standing position with arms 90° flexed, without weight, and after 30 seconds with weight.
Study NCT05293665 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx1-S vaccine
Description: ChAdOx1-S vaccine, 0.5 mL suspension with approximately 5.0 × 10˄10 viral particles, intramuscular injection
Study NCT06521970 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: forward head position
Description: The individual stands with his heels and pelvis in contact with the wall. The severity of kyphosis is interpreted by measuring the distance between the occiput and the wall in cm with the head facing forward. The intensity of kyphosis is classified as mild (≤5 cm), moderate (5.1-8 cm) and severe (>8 cm)
Study NCT05293665 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sinopharm BIBP
Description: Sinopharm BIBP COVID-19 vaccine, 0.5mL (4µg) suspension, intramuscular injection
Study NCT05794815 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Bifidobacterium infantis YLGB-1496 at 1x10 log CFU/day for 12 weeks
Study NCT04701619 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Immuno-inflammatory profile description in patients with ischemic stroke
Description: Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers
Study NCT05504252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Q2W~Nivolumab: 240 mg fixed dose over 30 minutes, IV administration every 2 weeks
Study NCT05504252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: FLOX, Q2W
Study NCT04969068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Interventions:The dose of remimazolam for each patient was determined by the response of the previously tested patients using the modified Dixon's up-and-down method.The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size). Duodenoscopy insertion was conducted when MOAA/S≤1.The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement).' Movement was defined as duodenoscopy insertion a failure was as gross purposeful muscular movement, coughing or vomiting occurring during or within 2 minutes of insertion of duodenoscopy. No movement was depicted when the reactions mentioned earlier were absent. If BIS>75 and MOAA/S > 1 when 3 min after the intravenous injection of remimazolam, it was considered a failure, and the patient received rescue sedation.
Study NCT04044898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA 5%
Description: prepare 5% ALA solution, apply topically to the affected area for 1.5 hours, single dose
Study NCT04044898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA 10%
Description: prepare 10% ALA solution, apply topically to the affected area for 3 hours, single dose
Study NCT05335746 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography (OCT-A)
Description: Optical coherence tomography angiography scanning will be done for all subjects in the study.
Study NCT05312164 — intervention group
Intervention type: DEVICE
Intervention: HF-OCT Imaging
Description: Subjects undergo HF-OCT imaging of stenosed coronary arteries
Study NCT05312164 — intervention group
Intervention type: DEVICE
Intervention: FFR Pressure Wire
Description: Subjects undergo FFR physiology assessment of stenosed coronary arteries
Study NCT05312164 — intervention group
Intervention type: DEVICE
Intervention: Angiography
Description: Subjects undergo angiography imaging of stenosed coronary arteries
Study NCT06470997 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample collection
Description: 6 collections of 5mL blood samples as part of usual care (pre-inclusion visit at Day-7, inclusion visit at Day 0, visit1 at Day 14, visit2 at Day 28, visit3 at Day 90, visit4 at 6 months) and 5 blood sample collections of 5 mL for proteomic analysis in the context of research (inclusion visit at Day 0, visit1 at Day 14, visit2 at Day 28, visit3 at Day 90, visit4 at 6 months)
Study NCT06470997 — intervention group
Intervention type: PROCEDURE
Intervention: Liver biopsy
Description: 1 liver biopsy performed as part of routine care and 1 additional sample for research: transparietal needle biopsy under ultrasound identification under local anesthesia by a radiologist, 1 to 2 cm per core taken, 2 cores are taken.
Study NCT05794815 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention consists of daily administration of 2g of maltodextrin, administered daily for 12-weeks)
Study NCT05253794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg
Description: oral tablet daily for 6 months
Study NCT05253794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet daily for 6 months
Study NCT05684341 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Connected Solution with H2S app which connects with blood glucose meter (BGM)
Description: Combination of the Insultrate titration module software, the H2S app for participants, and the H2S platform for healthcare professionals
Study NCT04961437 — intervention group
Intervention type: OTHER
Intervention: Diaphragmatic ultrasound and electrical impedance tomography
Description: A diaphragmatic ultrasound in a half sitting position. The diaphragmatic excursion and the thickening fraction of the right hemi-diaphragm will be measured.~- Acquisition of 10 minutes of regional pulmonary ventilation by electrical impedance tomography.
Study NCT05239663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganglioside-Monosialic Acid
Description: Standard (neo)adjuvant chemotherapy (Taxanes combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by taxanes) plus Ganglioside-Monosialic Acid 100mg+250ml normal saline (NS)
Study NCT05239663 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 250ml normal saline (NS)
Description: Standard (neo)adjuvant chemotherapy (Taxanes combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by taxanes) plus 250ml normal saline (NS)
Study NCT06413966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partially absorbable mesh
Description: - In this group, after bullectomy or blebectomy, partially absorbable mesh (ULTRAPRO size 15 x 15 cm, Ethicon) will be prepared and inserted into the pleural cavity through one of the working ports and placed at the apical part of the thoracic cage (over the staple line) using fixation device (ProTack™ 5 mm fixation device, Medtronic).
Study NCT06413966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apical pleurectomy
Description: - In apical pleurectomy group, after bullectomy or blebectomy, the parietal surface from the apex to the fifth rib was dissected and abraded using a curved dissector with a diathermy scratch pad. Abrasion was done until a uniform aspect of bloody pleura was obtained.
Study NCT06612008 — intervention group
Intervention type: DEVICE
Intervention: Mandibular Advancement Device
Description: MADs are custom-fitted oral appliances designed to reposition the mandible (lower jaw) forward during sleep, which helps to keep the airway open by preventing upper airway collapse.
Study NCT05619471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIO Imaging
Description: Skin conditions that are candidates for skin biopsies
Study NCT04798157 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: transcranial doppler
Description: Transcranial Doppler ultrasonography will be done using the ultrasound machine by placing a transducer over the relatively thinner temporal and occipital bones in order to visualize and evaluate the velocities at the circle of Willis.
Study NCT05623410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATGC-110
Description: ATGC-110 is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.
Study NCT05623410 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xeomin®
Description: Xeomin® is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.
Study NCT04331288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT150
Description: Intervention 1 includes PT150 with alcohol consumption
Study NCT04331288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage
Description: The alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in juice or another flavored beverage. Participants will be allowed 30 minutes to consume the beverages.
Study NCT05439746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microlyte® Matrix
Description: Microlyte® Matrix is indicated for the management of wounds and can be used over-the-counter for minor wounds such as abrasions and lacerations, minor cuts, and minor scalds and burns. Under the direction of a healthcare professional, Microlyte® Matrix may be used for more serious wounds such as partial and full thickness pressure ulcers, venous stasis ulcers, diabetic ulcers, first and second-degree burns, abrasions and lacerations, donor sites and surgical wounds. Microlyte® Matrix may be used over debrided and grafted partial thickness wounds.
Study NCT04828031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Patient with inflammatory bowel disease who have low vitamin D (25(OH)D less than or equal to 25 ng/mL) will take Vitamin D 50,000 IU by mouth every week for 12 weeks. Patients will fill out questionnaires to document disease activity score (HBI or Mayo score and sIBDQ) and have blood and stool samples collected before (Week 0), during (Week 8) and after (Week 12) vitamin D intervention.
Study NCT04155463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organic Diet
Description: Participants receive one week of organic food. Organic food is certified through the USDA's National Organic Program as produced without the use of synthetic pesticides, including glyphosate.
Study NCT04155463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Diet
Description: Participants receive one week of conventionally grown (non-organic) food.
Study NCT06458413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone Capsule Plus Capecitabine
Description: Utidelone Capsule: 60mg/m2/d, once daily, oral on an empty stomach, continuously administered for 1-5 days; Capecitabine tablets: 1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals, and continuously administered for 14 days from day 1 to day 14.~Every 21 days is a cycle .
Study NCT04993482 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This project contains a longitudinal observational study design. The investigator will collect data out of a group with type 2 diabetes mellitus patients and out of group with control adults on three time points (baseline, follow-up after one year, and follow-up after two years). Therefore, the investigator will only collect observational data and the participants will not be exposed to a certain intervention.
Study NCT06474156 — intervention group
Intervention type: BEHAVIORAL
Intervention: Multidimensional Family Therapy
Description: Multidimensional family therapy is a manualized,evidence-based, intensive intervention program with assessment and treatment modules focusing on four areas: (a) the individual adolescents' issues regarding substance use disorder, delinquency, and comorbid psychopathology, (b) the parents' child-rearing skills and personal functioning, (c) communication and relationship between adolescent and parent(s), and (d) interactions between family members and key social systems (Liddle, 2002).
Study NCT05442060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 μg OBI-833/100 μg OBI-821
Description: Each subject in the OBI-833/OBI-821 + erlotinib combination arm will be treated with OBI-833/OBI-821 weekly for 4 doses (Weeks 1, 2, 3, 4), then every 2 weeks for 2 doses (Weeks 6, 8), then every 4 weeks for 4 doses (Weeks 12, 16, 20, 24), and then every 8 weeks until documented disease progression, intolerable adverse events (AEs)/toxicity, consent withdrawal, death, loss to follow-up, or up to 80 weeks from randomization.
Study NCT05442060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib (150 mg daily)
Description: All subjects in both arms will continue to receive erlotinib as the background therapy (150 mg daily).
Study NCT05442060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg daily)
Description: All subjects in both arms will continue to receive erlotinib as the background therapy (150 mg daily).
Study NCT05070013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: All subjects will undergo three 1-week conditions of stimulation during nighttime sleep over the course of three consecutive weeks of in-home sleep: adaptive stimulation, open-loop stimulation and no stimulation.
Study NCT05070013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: All subjects will undergo three 1-week conditions of stimulation during nighttime sleep over the course of three consecutive weeks of in-home sleep: adaptive stimulation, open-loop stimulation and no stimulation.
Study NCT06431464 — intervention group
Intervention type: OTHER
Intervention: picosecond laser treatment + measurement with a multiphoton tomography system
Description: Patients with unwanted tattoos who plan a laser treatment will be recruited for measurements using a multiphoton-tomography system. These are scheduled 6 weeks and 12 weeks post-treatment.
Study NCT06431464 — intervention group
Intervention type: OTHER
Intervention: nanosecond laser treatment + measurement with a multiphoton tomography system
Description: Patients with unwanted tattoos who plan a laser treatment will be recruited for measurements using a multiphoton-tomography system. These are scheduled 6 weeks and 12 weeks post-treatment.
Study NCT04676061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethindrone acetate (NTA)
Description: norethindrone acetate, 5 mg tablet, orally, once daily for 7 consecutive days, every 4 weeks
Study NCT04676061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, tablet, orally, once daily for 7 consecutive days, every 4 weeks
Study NCT05759039 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medial patellofemoral ligament reconstruction
Description: Medial patellofemoral ligament reconstruction
Study NCT04617275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: PF-68882961 will be provided as tablets twice a day (BID)
Study NCT04617275 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator will be provided as tablets twice daily for 12 weeks
Study NCT06350760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active control condition
Description: The active control condition will be based on PROCARE protocol, which was put into practice in PROCARE-I, in 2021.
Study NCT06350760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROCARE-I+ 8-session
Description: The active control condition will be based on PROCARE protocol, which was put into practice in PROCARE-I, in 2021. In addition, PROCARE-I+ adds additional modules, which allow adolescents to be provided with tools to address the risk factors they present.
Study NCT05119179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Glucagon-like Peptide 1 Receptor Agonist
Study NCT05412004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT05412004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC